Identification of Iodotyrosines as Novel Substrates for the Thyroid Hormone Transporter MCT8.

IF 5.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Thyroid Pub Date : 2024-07-01 Epub Date: 2024-05-10 DOI:10.1089/thy.2023.0551
Stefan Groeneweg, Chantal Zevenbergen, Elaine C Lima de Souza, Ferdy S van Geest, Barbara Kloeckener-Gruissem, Endre Laczko, Simone M R Camargo, Marcel E Meima, Robin P Peeters, W Edward Visser
{"title":"Identification of Iodotyrosines as Novel Substrates for the Thyroid Hormone Transporter MCT8.","authors":"Stefan Groeneweg, Chantal Zevenbergen, Elaine C Lima de Souza, Ferdy S van Geest, Barbara Kloeckener-Gruissem, Endre Laczko, Simone M R Camargo, Marcel E Meima, Robin P Peeters, W Edward Visser","doi":"10.1089/thy.2023.0551","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Monocarboxylate transporter 8 (MCT8) is the most specific thyroid hormone transporter identified to date, deficiency of which has been associated with severe intellectual and motor disability and abnormal serum thyroid function tests. However, it is presently unknown if MCT8, similar to other thyroid hormone transporters, also accepts additional substrates, and if disruption of their transport may contribute to the observed phenotype. <b><i>Methods:</i></b> In this study, we aimed to identify such substrates by applying liquid chromatography-mass spectrometry-based metabolome analysis in lysates of control and MCT8-overexpressing <i>Xenopus</i> oocytes. A subset of identified candidate substrates were validated by direct transport studies in transiently transfected COS-1 cells and human fibroblasts, which endogenously express MCT8. Moreover, transport characteristics were determined, including transport saturation and cis-inhibition potency of thyroid hormone transport. <b><i>Results:</i></b> Metabolome analysis identified 21 m/z ratios, corresponding to 87 candidate metabolites, with a 2.0-times differential abundance in MCT8-injected oocytes compared with controls. These metabolites included 3,5-diiodotyrosine (DIT) and several amino acids, including glutamate and glutamine. In accordance, MCT8-expressing COS-1 cells had 2.2-times lower intracellular accumulation of [<sup>125</sup>I]-DIT compared with control cells. This effect was largely blocked in the presence of 3,3',5-triiodothyronine (T3) (IC<sub>50</sub>: 2.5 ± 1.5 µM) or thyroxine (T4) (IC<sub>50</sub>: 5.8 ± 1.3 µM). Conversely, increasing concentrations of DIT enhanced the accumulation of T3 and T4. The MCT8-specific inhibitor silychristin increased the intracellular accumulation of DIT in human fibroblasts. COS-1 cells expressing MCT8 also exhibited a 50% reduction in intracellular accumulation of [<sup>125</sup>I]-3-monoiodotyrosine (MIT). In contrast, COS-1 cells expressing MCT8 did not alter the intracellular accumulation of [<sup>3</sup>H]-glutamate or [<sup>3</sup>H]-glutamine. However, studies in human fibroblasts showed a 1.5-1.9 times higher glutamate uptake in control fibroblasts compared with fibroblasts derived from patients with MCT8 deficiency, which was not affected in the presence of silychristin. <b><i>Conclusions:</i></b> Taken together, our results suggest that the iodotyrosines DIT and MIT can be exported by MCT8. MIT and DIT interfere with MCT8-mediated transport of thyroid hormone <i>in vitro</i> and <i>vice versa</i>. Future studies should elucidate if MCT8, being highly expressed in thyroidal follicular cells, also transports iodotyrosines <i>in vivo</i>.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"931-941"},"PeriodicalIF":5.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/thy.2023.0551","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Monocarboxylate transporter 8 (MCT8) is the most specific thyroid hormone transporter identified to date, deficiency of which has been associated with severe intellectual and motor disability and abnormal serum thyroid function tests. However, it is presently unknown if MCT8, similar to other thyroid hormone transporters, also accepts additional substrates, and if disruption of their transport may contribute to the observed phenotype. Methods: In this study, we aimed to identify such substrates by applying liquid chromatography-mass spectrometry-based metabolome analysis in lysates of control and MCT8-overexpressing Xenopus oocytes. A subset of identified candidate substrates were validated by direct transport studies in transiently transfected COS-1 cells and human fibroblasts, which endogenously express MCT8. Moreover, transport characteristics were determined, including transport saturation and cis-inhibition potency of thyroid hormone transport. Results: Metabolome analysis identified 21 m/z ratios, corresponding to 87 candidate metabolites, with a 2.0-times differential abundance in MCT8-injected oocytes compared with controls. These metabolites included 3,5-diiodotyrosine (DIT) and several amino acids, including glutamate and glutamine. In accordance, MCT8-expressing COS-1 cells had 2.2-times lower intracellular accumulation of [125I]-DIT compared with control cells. This effect was largely blocked in the presence of 3,3',5-triiodothyronine (T3) (IC50: 2.5 ± 1.5 µM) or thyroxine (T4) (IC50: 5.8 ± 1.3 µM). Conversely, increasing concentrations of DIT enhanced the accumulation of T3 and T4. The MCT8-specific inhibitor silychristin increased the intracellular accumulation of DIT in human fibroblasts. COS-1 cells expressing MCT8 also exhibited a 50% reduction in intracellular accumulation of [125I]-3-monoiodotyrosine (MIT). In contrast, COS-1 cells expressing MCT8 did not alter the intracellular accumulation of [3H]-glutamate or [3H]-glutamine. However, studies in human fibroblasts showed a 1.5-1.9 times higher glutamate uptake in control fibroblasts compared with fibroblasts derived from patients with MCT8 deficiency, which was not affected in the presence of silychristin. Conclusions: Taken together, our results suggest that the iodotyrosines DIT and MIT can be exported by MCT8. MIT and DIT interfere with MCT8-mediated transport of thyroid hormone in vitro and vice versa. Future studies should elucidate if MCT8, being highly expressed in thyroidal follicular cells, also transports iodotyrosines in vivo.

鉴定作为甲状腺激素转运体 MCT8 新型底物的碘酪氨酸。
背景单羧酸盐转运体8(MCT8)是迄今为止发现的最特异的甲状腺激素转运体,缺乏该转运体会导致严重的智力和运动障碍以及血清甲状腺功能检测异常。然而,目前还不知道 MCT8 是否也像其他甲状腺激素转运体一样接受其他底物,也不知道它们的转运中断是否会导致观察到的表型。方法 在本研究中,我们的目的是通过对对照组和 MCT8 过表达的爪蟾卵母细胞裂解物进行基于 LC-MS 的代谢组分析来确定这些底物。通过在瞬时转染的 COS-1 细胞和内源表达 MCT8 的人类成纤维细胞中进行直接转运研究,验证了已确定的候选底物子集。此外,还测定了转运特征,包括甲状腺激素转运的转运饱和度和顺式抑制效力。结果 代谢组分析确定了 21 个 m/z 比值,对应 87 种候选代谢物,与对照组相比,MCT8 注射卵母细胞中这些代谢物的丰度相差 2.0 倍。这些代谢物包括 3,5-二碘酪氨酸(DIT)和几种氨基酸,包括谷氨酸和谷氨酰胺。与对照细胞相比,表达 MCT8 的 COS-1 细胞内[125I]-DIT 的积累量要低 2.2 倍。在有 T3(IC50:2.5±1.5 µM)或 T4(IC50:5.8±1.3 µM)存在的情况下,这种效应在很大程度上被阻断。相反,DIT 浓度的增加会增强 T3 和 T4 的积累。MCT8 特异性抑制剂 silychristin 增加了 DIT 在人成纤维细胞内的积累。表达 MCT8 的 COS-1 细胞的 [125I]-3- 单碘酪氨酸(MIT)细胞内积累也减少了 50%。相反,表达 MCT8 的 COS-1 细胞不会改变 [3H]- 谷氨酸或 [3H]- 谷氨酰胺在细胞内的积累。然而,对人类成纤维细胞的研究表明,与来自 MCT8 缺乏症患者的成纤维细胞相比,对照组成纤维细胞的谷氨酸摄取量要高出 1.5-1.9 倍,而在西利司汀存在的情况下,谷氨酸摄取量不受影响。结论 综上所述,我们的研究结果表明,碘酪氨酸 DIT 和 MIT 可由 MCT8 输出。MIT 和 DIT 会干扰 MCT8 介导的甲状腺激素体外转运,反之亦然。未来的研究应阐明在甲状腺滤泡细胞中高表达的MCT8是否也能在体内转运碘酪氨酸。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Thyroid
Thyroid 医学-内分泌学与代谢
CiteScore
12.30
自引率
6.10%
发文量
195
审稿时长
6 months
期刊介绍: This authoritative journal program, including the monthly flagship journal Thyroid, Clinical Thyroidology® (monthly), and VideoEndocrinology™ (quarterly), delivers in-depth coverage on topics from clinical application and primary care, to the latest advances in diagnostic imaging and surgical techniques and technologies, designed to optimize patient care and outcomes. Thyroid is the leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. The Journal delivers the latest findings on topics from primary care to clinical application, and is the exclusive source for the authoritative and updated American Thyroid Association (ATA) Guidelines for Managing Thyroid Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信